Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Ricolinostat in Healthy Chinese Adults
NCT05193851Phase 1Completed
- Sponsor
- Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.
- Start
- Jan 2022
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ricolinostat in peripheral nerve disorder, sponsored by Beijing 3E-Regenacy Pharmaceuticals Co., Ltd. Primary endpoint: safety of dosed subjects at 1 week. Started Jan 2022; status: completed.
02
Drugs
ricolinostat
03
Conditions
peripheral nerve disorder
Beyond the preview
Go deeper on NCT05193851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05193851.